Juniper Genomics raises $4.6M for whole-genome embryo screening platform

Juniper Genomics, a Velocity Fund portfolio company, has officially launched with $4.6M in seed funding to commercialize the first embryo test that combines whole genome and transcriptome sequencing offering unprecedented insight into embryo viability and health.

Co-founded by Jeremy Grushcow PhD, JD (CEO), Carolyn Quinlan, MSc (VP of Bioethics), Dr. Lee Shulman (Medical Director), Juniper Genomics test analyzes all of the millions of genetic changes unique to each embryo, identifying variants linked to IVF failure, miscarriage, and serious health conditions.

Their approach includes trio analysis (embryo + both biological parents) and focuses on clinically relevant insights that directly impact pregnancy outcomes and cause disease, while avoiding polygenic risk scores which do not predict individual outcomes.

This funding was led by Company Ventures, with participation from Innospark Ventures, MBX Capital , Amboy Street Ventures, Dria Ventures, and Blue Collective, the funding will support Juniper Genomics commercial rollout, team expansion, and North American research initiatives.

Backed by Genome Canada and Génome Québec, Juniper Genomics is blending cutting-edge science with ethical, evidence-based reproductive care.

Learn more